Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients

• DOI: 10.1186/s12981-016-0091-1
• Publication Date: 2016-02-10T08:41:30Z
• Authors: Hongwei Zhang; Ronghua Jin; Cheng Yao; Tong Zhang; Meixia Wang; Wei Xia; Haiyan Peng; Xiaojuan Wang; Rongjian Lu; Changjin Wang; Dong Xie; Hao Wu
• Keywords: Regimen; Pharmacodynamics

Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety albuvirtide (ABT), an HIV-1 fusion inhibitor with half life 11–12 days in human. ABT was evaluated 7-week, open-label randomized trial, combining LPV/r. Twenty HIV-1-infected adults were assigned to two dose groups, receiving (160 or 320 mg) given weekly LPV/r twice daily. At week 7, decline RNA from baseline 1.9 (1.3–2.3) log10 2.2 (1.6–2.7) copies/ml, suppression below 50 copies/ml achieved 11.1 % (1/9) 55.6 (5/9) patients, 160 mg group respectively. A clear dose-efficacy correlation demonstrated. is two-drug regimen be tested larger patient population.